The anti-CXCL12 aptamer can inhibit tumor-supporting pathways and mobilize CLL cells away from their protective microenvironment, thereby inducing apoptosis and chemotherapy sensitization in these leukemic cells [48]. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.